All-cause mortality and factors associated with it in finnish patients with type 1 diabetes

被引:0
|
作者
Putula, Elena [1 ,2 ]
Kauppala, Tuuli [3 ]
Vanhamaki, Sini [3 ]
Haapakoski, Jaason [3 ]
Laatikainen, Tiina [3 ,4 ]
Metso, Saara [1 ,2 ]
机构
[1] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland
[2] Tampere Univ Hosp, Dept Internal Med, Tampere, Finland
[3] Finnish Inst Hlth & Welf, THL, Helsinki, Finland
[4] Univ Eastern Finland, Fac Hlth Sci, Joensuu, Finland
关键词
Cardiovascular diseases; Glycaemic control; Mortality; Psychiatric comorbidities; Substance abuse; Type; 1; diabetes; EXCESS MORTALITY; CARDIOVASCULAR-DISEASES; NATIONWIDE COHORT; GLYCEMIC CONTROL; LIFE EXPECTANCY; CHILDHOOD; TRENDS; DYSLIPIDEMIA; PREVALENCE; PEOPLE;
D O I
10.1016/j.jdiacomp.2024.108881
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: To assess the effect of comorbidities, risk classification for chronic kidney disease (CKD) according to albuminuria and eGFR, HbA1c and LDL-cholesterol levels on all-cause mortality in patients with type 1 diabetes (DM1). Methods: The study included all 45,801 DM1 patients from the Finnish Diabetes Registry during 2018-2022. Mortality of patients with DM1 was compared with mortality in non-diabetic population in Finland by estimating standardized mortality rates (SMRs). Poisson regression model was used to estimate the effect of risk factors on the SMR. Results: A total of 2469 patients died during follow-up. SMR for the total cohort was 1.84 (95 % CI 1.77-1.92) peaking at the age of 30-49 years. The coverage of HbA1c values was 98 %, that of LDL-cholesterol 94 %, and UACR and eGFR 80 %. In a multivariate analysis, assessing the effect on mortality, the rate ratio for end-stage renal disease was 2.66, cardiovascular diseases 1.92, mental and behavioural disorders 1.64, foot complications 1.51, high or very high risk for CKD 3.64, LDL-cholesterol >2.6 mmol/l 1.33, and HbA1c >8 % (64 mmol/mol) 1.27. Conclusions: There's substantial excess mortality due to DM1 in Finland. Interventions should focus on addressing both renal and cardiovascular risk factors but also pay more attention to mental health.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Erythropoietin (EPO) haplotype associated with all-cause mortality in a cohort of Italian patients with Type-2 Diabetes
    Alberto Montesanto
    Anna Rita Bonfigli
    Maria De Luca
    Paolina Crocco
    Paolo Garagnani
    Elena Marasco
    Chiara Pirazzini
    Cristina Giuliani
    Fabio Romagnoli
    Claudio Franceschi
    Giuseppe Passarino
    Roberto Testa
    Fabiola Olivieri
    Giuseppina Rose
    Scientific Reports, 9
  • [42] Low skeletal muscle mass is associated with the risk of all-cause mortality in patients with type 2 diabetes mellitus
    Miyake, Hitomi
    Kanazawa, Ippei
    Tanaka, Ken-ichiro
    Sugimoto, Toshitsugu
    THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2019, 10
  • [43] Erythropoietin (EPO) haplotype associated with all-cause mortality in a cohort of Italian patients with Type-2 Diabetes
    Montesanto, Alberto
    Bonfigli, Anna Rita
    De Luca, Maria
    Crocco, Paolina
    Garagnani, Paolo
    Marasco, Elena
    Pirazzini, Chiara
    Giuliani, Cristina
    Romagnoli, Fabio
    Franceschi, Claudio
    Passarino, Giuseppe
    Testa, Roberto
    Olivieri, Fabiola
    Rose, Giuseppina
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [44] All-cause and cause-specific mortality, cardiovascular diseases, and prognostic factors in adult-onset type 1 diabetes
    Wei, Y.
    Andersson, T.
    Tuomi, T.
    Nystrom, T.
    Carlsson, S.
    DIABETOLOGIA, 2024, 67 : S48 - S48
  • [45] Luteolin intake is negatively associated with all-cause and cardiac mortality among patients with type 2 diabetes mellitus
    Wenbin Zhang
    Duanbin Li
    Yu Shan
    Yecheng Tao
    Qingqing Chen
    Tianli Hu
    Menghan Gao
    Zhezhe Chen
    Hangpan Jiang
    Changqin Du
    Min Wang
    Kai Guo
    Diabetology & Metabolic Syndrome, 15
  • [46] Albuminuria Increases All-Cause Mortality in Japanese Patients with Type 2 Diabetes Mellitus
    Miyake, Hitomi
    Kanazawa, Ippei
    Sugimoto, Toshitsugu
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (09):
  • [47] Resistin, major cardiovascular events and all-cause mortality in patients with type 2 diabetes
    Menzaghi, C.
    Bacci, S.
    Salvemini, L.
    Powers, C.
    Fontana, A.
    De Cosmo, S.
    Pellegrini, F.
    Doria, A.
    Trischitta, V.
    DIABETOLOGIA, 2012, 55 : S62 - S63
  • [48] Serum Resistin, Cardiovascular Disease and All-Cause Mortality in Patients with Type 2 Diabetes
    Menzaghi, Claudia
    Bacci, Simonetta
    Salvemini, Lucia
    Mendonca, Christine
    Palladino, Giuseppe
    Fontana, Andrea
    De Bonis, Concetta
    Marucci, Antonella
    Goheen, Elizabeth
    Prudente, Sabrina
    Morini, Eleonora
    Rizza, Stefano
    Kanagaki, Alyssa
    Fini, Grazia
    Mangiacotti, Davide
    Federici, Massimo
    De Cosmo, Salvatore
    Pellegrini, Fabio
    Doria, Alessandro
    Trischitta, Vincenzo
    PLOS ONE, 2013, 8 (06):
  • [49] Vitamin D Status and All-Cause Mortality in Patients With Type 2 Diabetes in China
    Fan, Yuxin
    Ding, Li
    Zhang, Yalan
    Shu, Hua
    He, Qing
    Cui, Jingqiu
    Hu, Gang
    Liu, Ming
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [50] Development and Validation of a Predicting Model of All-Cause Mortality in Patients With Type 2 Diabetes
    De Cosmo, Salvatore
    Copetti, Massimiliano
    Lamacchia, Olga
    Fontana, Andrea
    Massa, Michela
    Morini, Eleonora
    Pacilli, Antonio
    Fariello, Stefania
    Palena, Antonio
    Rauseo, Anna
    Viti, Rafaella
    Di Paola, Rosa
    Menzaghi, Claudia
    Cignarelli, Mauro
    Pellegrini, Fabio
    Trischitta, Vincenzo
    DIABETES CARE, 2013, 36 (09) : 2830 - 2835